×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
Simply Wall Street
Key Insights Stoke Therapeutics' Annual General Meeting to take place on 5th of June CEO Ed Kaye's total compensation...
3 days ago
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by...
1 month ago
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease ...
Yahoo Finance
BEDFORD, Mass., March 25, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying...
2 months ago
Wilson Sonsini Advises Stoke Therapeutics on IP Matters Related to Upsized Public Offering
Wilson Sonsini
On March 28, 2024, Stoke Therapeutics, a biotechnology company focused on developing RNA-based medicines to treat severe diseases,...
2 months ago
Longtime biotech leader Ed Kaye is chasing another rare-disease drug for ailing kids
The Business Journals
The CEO of Stoke Therapeutics began his career treating rare pediatric genetic diseases. From there he joined Genzyme, then Sarepta...
3 days ago
Stoke's shares shoot up 90% as epilepsy drug slashes convulsive seizures
Fierce Biotech
Investors are stocking up on Stoke Therapeutics, sending the biotech's shares jumping over 90% in premarket trading on the back of positive...
2 months ago
Stoke Therapeutics (NASDAQ:STOK) Trading Up 5.3%
MarketBeat
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 5.3%
2 days ago
Stoke Therapeutics Chief Financial Officer Stephen Tulipano Resigns
MarketWatch
By Colin Kellaher Stoke Therapeutics on Monday said its chief financial officer, Stephen Tulipano, has resigned, effective May 7.
1 month ago
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
Yahoo Finance
BEDFORD, Mass., April 04, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying...
1 month ago
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Business Wire
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by...
2 weeks ago